24368217|t|APOE modulates the effect of estrogen therapy on Abeta accumulation EFAD-Tg mice.
24368217|a|The post-menopausal loss of estrogen is key in the increased incidence of Alzheimer's disease (AD) in women. However, estrogen therapy (ET) clinical trials have produced conflicting results. The APOE gene of apolipoprotein E (apoE) likely modulates the effects of ET in AD. APOE4 is the greatest genetic risk factor for AD, increasing risk up to 15-fold compared with APOE3, and the negative effect of APOE4 on AD risk and neuropathology is greater in women than men. The interactive effects of APOE and ET may converge on modulation of amyloid-beta (Abeta) levels, as independently both the loss of estrogen and APOE4 increases Abeta accumulation. Thus, in this study, 3-month old female EFAD mice (5XFAD mice crossed with apoE-targeted replacement mice), which express increased levels of Abeta42 and human APOE were ovariectomized and treated for 3 months with either 17-beta estradiol (OVX(ET+), 0.25mg total) or vehicle control (OVX(ET-)) and the effects on Abeta accumulation were determined. Compared to the OVX(ET-) cohort, in the OVX(ET+) cohort, extracellular amyloid and Abeta deposition in the hippocampus and cortex were decreased with APOE2 and APOE3, but were increased with APOE4 by IHC. Biochemical analysis demonstrated increased total and insoluble Abeta levels with APOE4, and decreased soluble Abeta42 levels with both APOE3 and APOE4, after ET. These data suggest that ET administered at menopause may benefit APOE4 negative women by decreasing extracellular and soluble Abeta42. However, for APOE4 carriers, the efficacy of ET will be dependent on the relative impact of extracellular and soluble Abeta on AD-induced neurodegeneration. 
24368217	0	4	APOE	Gene	348
24368217	49	54	Abeta	Gene	11820
24368217	68	72	EFAD	Disease	
24368217	76	80	mice	Species	10090
24368217	156	175	Alzheimer's disease	Disease	MESH:D000544
24368217	177	179	AD	Disease	MESH:D000544
24368217	184	189	women	Species	9606
24368217	277	281	APOE	Gene	348
24368217	290	306	apolipoprotein E	Gene	348
24368217	308	312	apoE	Gene	348
24368217	352	354	AD	Disease	MESH:D000544
24368217	356	361	APOE4	Gene	348
24368217	402	404	AD	Disease	MESH:D000544
24368217	450	455	APOE3	Gene	348
24368217	484	489	APOE4	Gene	348
24368217	493	495	AD	Disease	MESH:D000544
24368217	534	539	women	Species	9606
24368217	545	548	men	Species	9606
24368217	577	581	APOE	Gene	348
24368217	633	638	Abeta	Gene	11820
24368217	695	700	APOE4	Gene	348
24368217	711	716	Abeta	Gene	11820
24368217	771	775	EFAD	Disease	
24368217	776	780	mice	Species	10090
24368217	788	792	mice	Species	10090
24368217	806	810	apoE	Gene	348
24368217	832	836	mice	Species	10090
24368217	873	880	Abeta42	Gene	351
24368217	885	890	human	Species	9606
24368217	891	895	APOE	Gene	348
24368217	953	970	17-beta estradiol	Chemical	MESH:D004958
24368217	1045	1050	Abeta	Gene	11820
24368217	1164	1169	Abeta	Gene	351
24368217	1241	1246	APOE3	Gene	348
24368217	1272	1277	APOE4	Gene	348
24368217	1350	1355	Abeta	Gene	351
24368217	1368	1373	APOE4	Gene	348
24368217	1397	1404	Abeta42	Gene	351
24368217	1422	1427	APOE3	Gene	348
24368217	1432	1437	APOE4	Gene	348
24368217	1514	1519	APOE4	Gene	348
24368217	1529	1534	women	Species	9606
24368217	1575	1582	Abeta42	Gene	351
24368217	1597	1602	APOE4	Gene	348
24368217	1702	1707	Abeta	Gene	351
24368217	1711	1713	AD	Disease	MESH:D000544
24368217	1722	1739	neurodegeneration	Disease	MESH:D019636
24368217	Positive_Correlation	MESH:D000544	348
24368217	Negative_Correlation	MESH:D004958	11820
24368217	Positive_Correlation	11820	348
24368217	Association	MESH:D019636	351
24368217	Positive_Correlation	348	351

